Holen Sie sich die Stockscreener-App
177.35
0.76%
1.33
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$176.02
Offen:
$176.29
24-Stunden-Volumen:
1.24M
Relative Volume:
0.95
Marktkapitalisierung:
$26.03B
Einnahmen:
$9.53B
Nettoeinkommen (Verlust:
$1.29B
KGV:
20.14
EPS:
8.8057
Netto-Cashflow:
$1.97B
1W Leistung:
+2.53%
1M Leistung:
-4.29%
6M Leistung:
+24.02%
1J Leistung:
+49.52%
1-Tages-Spanne:
$175.69
$178.41
1-Wochen-Bereich:
$171.22
$181.77
52-Wochen-Spanne:
$115.25
$202.41
Biogen Inc Stock (BIIB) Company Profile
Firmenname
Biogen Inc
Sektor
Telefon
(781) 464-2000
Adresse
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB vs LLY, JNJ, ABBV, AZN, MRK
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
177.35 | 26.03B | 9.53B | 1.29B | 1.97B | 8.8057 |
LLY
Lilly Eli Co
|
927.03 | 828.17B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
234.18 | 564.05B | 96.36B | 21.04B | 19.70B | 8.6488 |
ABBV
Abbvie Inc
|
208.38 | 368.57B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
204.80 | 317.61B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
119.07 | 294.09B | 64.93B | 18.26B | 12.36B | 7.2751 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-14 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2026-02-20 | Eingeleitet | Barclays | Equal Weight |
| 2026-02-09 | Bestätigt | H.C. Wainwright | Buy |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-10 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2025-11-06 | Hochstufung | Stifel | Hold → Buy |
| 2025-09-25 | Eingeleitet | Jefferies | Buy |
| 2025-07-21 | Fortgesetzt | Truist | Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-04-04 | Herabstufung | Argus | Buy → Hold |
| 2025-02-11 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-01-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-09 | Herabstufung | Jefferies | Buy → Hold |
| 2024-11-18 | Herabstufung | Needham | Buy → Hold |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-10-31 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-02-14 | Bestätigt | Needham | Buy |
| 2024-02-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2023-12-20 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-24 | Bestätigt | UBS | Buy |
| 2023-05-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-04-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Hochstufung | Goldman | Neutral → Buy |
| 2022-10-13 | Hochstufung | Stifel | Hold → Buy |
| 2022-10-07 | Hochstufung | Argus | Hold → Buy |
| 2022-09-28 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Hochstufung | Mizuho | Neutral → Buy |
| 2022-09-28 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Bestätigt | Barclays | Equal Weight |
| 2022-02-04 | Bestätigt | BofA Securities | Neutral |
| 2022-02-04 | Bestätigt | Cowen | Outperform |
| 2022-02-04 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-04 | Bestätigt | Needham | Buy |
| 2022-02-04 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-04 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Bestätigt | Robert W. Baird | Neutral |
| 2022-02-04 | Bestätigt | Wedbush | Neutral |
| 2022-02-04 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-02-04 | Bestätigt | Wolfe Research | Peer Perform |
| 2022-01-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-01-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-06-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Bestätigt | Truist | Buy |
| 2021-06-11 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-08 | Hochstufung | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Bestätigt | Barclays | Equal Weight |
| 2021-06-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-08 | Bestätigt | Jefferies | Buy |
| 2021-06-08 | Bestätigt | Morgan Stanley | Overweight |
| 2021-06-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Bestätigt | Stifel | Buy |
| 2021-06-08 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-06-07 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Herabstufung | DZ Bank | Buy → Hold |
| 2021-01-29 | Hochstufung | Stifel | Hold → Buy |
| 2020-11-10 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-11-09 | Herabstufung | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-11-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-04 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Hochstufung | Jefferies | Hold → Buy |
| 2020-11-04 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-07-27 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-04-23 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-01-27 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Herabstufung | Robert W. Baird | Neutral → Underperform |
Alle ansehen
Biogen Inc Aktie (BIIB) Neueste Nachrichten
Biogen Inc. (NASDAQ:BIIB) Rating Balance Draws Nasdaq Composite Attention - Kalkine Media
Biogen Inc. (NASDAQ:BIIB) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Should Value Investors Buy Biogen (BIIB) Stock? - Yahoo Finance
Biogen CEO: China will match U.S. drug innovation in five to 10 years - The Business Journals
Biogen Inc. stock underperforms Thursday when compared to competitors - MarketWatch
'There's a lot of momentum': Biogen acquisition translates into West Coast hub with immunology focus - The Business Journals
This Healthcare Stock Has Made Long-Term Investors Rich -- Can It Keep Doing It? - The Motley Fool
How Biogen’s Alloy ASO Deal Could Shape Its Neurology Pipeline Will Impact Biogen (BIIB) Investors - simplywall.st
Sumitomo Mitsui Trust Group Inc. Lowers Holdings in Biogen Inc. $BIIB - MarketBeat
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Piper Sandler upgrades Biogen stock rating on acquisition strength By Investing.com - Investing.com South Africa
Piper Sandler upgrades Biogen stock rating on acquisition strength - Investing.com
Biogen stock upgraded at Piper Sandler (BIIB:NASDAQ) - Seeking Alpha
Biogen Secures FDA Nod for Higher Dose of SMA Drug Spinraza - Eastern Progress
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Biogen, Birkenstock, Fastly, Ford, Lennox International, Netskope, SanDisk, Tesla, and More - 24/7 Wall St.
Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term - Yahoo Finance
This Tesla Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For TuesdayBiogen (NASDAQ:BIIB), Croc - Benzinga
Apellis (APLS) board recommends $41 cash takeover by Biogen with up to $4 CVR - Stock Titan
Biogen (NASDAQ: APLS) bids $41 per share plus up to $4 CVR for Apellis - Stock Titan
Analyst recommendations: Biogen, Ford, Ge Vernova, Booking, Comcast… - marketscreener.com
Biogen Inc. stock (US09062X1037): Is Alzheimer's pipeline strength now the real test for upside? - AD HOC NEWS
Paragon Capital Management Acquires 6,686 Shares in Biogen - National Today
Will AbbVie's Neuroscience Franchise Aid Top-line Growth in Q1? - TradingView — Track All Markets
6,686 Shares in Biogen Inc. $BIIB Acquired by Paragon Capital Management Inc. - MarketBeat
Biogen Inc. stock (US09062X1037): Does its neurology pipeline hold the key to renewed growth for U.S. investors? - AD HOC NEWS
Biogen to acquire Apellis for $5.6B to strengthen immunology portfolio - MSN
Biogen Inc. stock underperforms Friday when compared to competitors - MarketWatch
Biogen Inc (XSWX:BIIB)Valuation Measures & Financial Statistics - GuruFocus
Biogen Inc. stock (US09062X1037): Is the neurology focus strong enough to unlock new upside? - AD HOC NEWS
Today's Analyst Ratings Update for Biogen (BIIB): Key Changes | BIIB Stock News - GuruFocus
Today's Analyst Ratings Update for Biogen (BIIB): Key Changes | - GuruFocus
Biogen’s Alloy Antisense Deal Adds New Dimension To Genetic Medicine Bet - Sahm
Apellis Pharmaceuticals (APLS) hits 2-year high on 140% upside from Biogen merger - MSN
Boost for Cambridge as US company Alloy Therapeutics shows real Vigilance - Business Weekly
Is It Time To Reassess Biogen (BIIB) After Its 49% One Year Share Price Surge - simplywall.st
Biogen strengthens case for BDCA2 as a cutaneous lupus target - biocentury.com
Biogen Inc. stock rises Wednesday, still underperforms market - MarketWatch
Biogen to use Alloy Therapeutics’ Anticlastic ASO platform - BioWorld News
Biogen (BIIB) Partners With Alloy Therapeutics on Antisense Drug Platform - MEXC Exchange
Biogen, Investors Reach Deal In Alzheimer's Drug Litigation - Law360
Biogen (NASDAQ: APLS) readies tender offer for Apellis under March 31, 2026 deal - Stock Titan
Why Biogen (BIIB) could beat earnings estimates again - MSN
Biogen’s ASO Strategy: How a $27B Giant is Investing $100M in a New Platform - Bitget
Why Biogen (BIIB) Could Beat Earnings Estimates Again - Yahoo Finance
Alloy Therapeutics and Biogen Announce Multi-Target Collaboration - National Today
Biogen taps Alloy platform to push antisense drug pipeline forward - MSN
Alloy Therapeutics Enters into Multi-Target Collaboration and License Agreement with Biogen for Use of Alloy’s AntiClastic™ ASO Platform - BioSpace
What Is Driving Biogen’s Recent Drop and What Comes Next - Trefis
Biogen (BIIB) Stock Signs ASO Platform Deal With Alloy Therapeutics - CoinCentral
Biogen Taps Alloy Platform To Push Antisense Drug Pipeline Forward - Benzinga
RBC Capital Adjusts Biogen Price Target to $213 From $233, Maintains Outperform Rating - marketscreener.com
Finanzdaten der Biogen Inc-Aktie (BIIB)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.25%
0.66%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):